HDAC6 and follicular lymphoma: These results are partially consistent with published data from Lee and collaborators [28] that demonstrated that a combination of a selective HDAC6 inhibitor and ibrutinib (a tyrosine kinase inhibitor) was effective in reducing cell viability and upregulating cellular apoptosis in non-Hodgkin lymphoma and follicular lymphoma.